ATE537141T1 - Bicycloesterderivat - Google Patents
BicycloesterderivatInfo
- Publication number
- ATE537141T1 ATE537141T1 AT05704327T AT05704327T ATE537141T1 AT E537141 T1 ATE537141 T1 AT E537141T1 AT 05704327 T AT05704327 T AT 05704327T AT 05704327 T AT05704327 T AT 05704327T AT E537141 T1 ATE537141 T1 AT E537141T1
- Authority
- AT
- Austria
- Prior art keywords
- pharmaceutically acceptable
- acceptable salts
- bicycloester derivative
- bicycloester
- derivatives
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 abstract 2
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 abstract 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 abstract 1
- AKFNKZFJBFQFAA-DIOPXHOYSA-N ethyl 4-[[2-[(2s,4s)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino]bicyclo[2.2.2]octane-1-carboxylate Chemical compound C1CC(C(=O)OCC)(CC2)CCC12NCC(=O)N1C[C@@H](F)C[C@H]1C#N AKFNKZFJBFQFAA-DIOPXHOYSA-N 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004029856 | 2004-02-05 | ||
| PCT/JP2005/001377 WO2005075421A1 (ja) | 2004-02-05 | 2005-02-01 | ビシクロエステル誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE537141T1 true ATE537141T1 (de) | 2011-12-15 |
Family
ID=34835968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05704327T ATE537141T1 (de) | 2004-02-05 | 2005-02-01 | Bicycloesterderivat |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US7754757B2 (de) |
| EP (1) | EP1712547B1 (de) |
| JP (1) | JP3954626B2 (de) |
| KR (1) | KR101130433B1 (de) |
| CN (2) | CN101684089A (de) |
| AT (1) | ATE537141T1 (de) |
| AU (1) | AU2005210285B2 (de) |
| BR (1) | BRPI0506622A (de) |
| CA (1) | CA2554493C (de) |
| CY (1) | CY1112550T1 (de) |
| DK (1) | DK1712547T3 (de) |
| ES (1) | ES2375625T3 (de) |
| HK (1) | HK1100511A1 (de) |
| HR (1) | HRP20120006T1 (de) |
| NO (1) | NO20063486L (de) |
| NZ (1) | NZ548440A (de) |
| PL (1) | PL1712547T3 (de) |
| PT (1) | PT1712547E (de) |
| RS (1) | RS52163B (de) |
| SI (1) | SI1712547T1 (de) |
| WO (1) | WO2005075421A1 (de) |
| ZA (1) | ZA200606237B (de) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1712547T1 (sl) * | 2004-02-05 | 2012-04-30 | Kyorin Seiyaku Kk | Bicikloestrski derivat |
| US7514571B2 (en) * | 2004-02-27 | 2009-04-07 | Kyorin Pharmaceutical Co., Ltd. | Bicyclo derivative |
| GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
| CA2645154C (en) * | 2006-03-08 | 2011-11-29 | Kyorin Pharmaceutical Co., Ltd. | Method for producing aminoacetylpyrrolidinecarbonitrile derivative and production intermediate thereof |
| JP2010120851A (ja) * | 2007-02-09 | 2010-06-03 | Kyorin Pharmaceut Co Ltd | 二量化シクロ誘導体 |
| ATE550319T1 (de) | 2007-03-22 | 2012-04-15 | Kyorin Seiyaku Kk | Verfahren zur herstellung eines aminoacetylpyrrolidincarbonitrilderivats |
| KR101361427B1 (ko) | 2007-04-03 | 2014-02-10 | 미쓰비시 타나베 파마 코퍼레이션 | 디펩티딜 펩티다아제 4 저해 화합물과 감미료와의 병용 |
| CL2008003653A1 (es) * | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| EP2322499A4 (de) * | 2008-08-07 | 2011-12-21 | Kyorin Seiyaku Kk | Verfahren zur herstellung eines bicyclo-[2,2,2]-octylaminderivats |
| KR20110044780A (ko) * | 2008-08-14 | 2011-04-29 | 교린 세이야꾸 가부시키 가이샤 | 안정화된 의약 조성물 |
| MX2011001525A (es) | 2008-08-15 | 2011-03-29 | Boehringer Ingelheim Int | Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab. |
| CA2737296A1 (en) * | 2008-09-16 | 2010-03-25 | Kyorin Pharmaceutical Co., Ltd. | Method for purifying aminoacetylpyrrolidinecarbonitrile derivative and salt thereof |
| TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
| AU2010204144B2 (en) * | 2009-01-09 | 2012-02-16 | Orchid Research Laboratories Ltd. | Dipeptidyl peptidase IV inhibitors |
| AR075204A1 (es) | 2009-01-29 | 2011-03-16 | Boehringer Ingelheim Int | Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2 |
| US20120094894A1 (en) | 2009-02-13 | 2012-04-19 | Boehringer Ingelheim International Gmbh | Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics |
| JPWO2010110436A1 (ja) * | 2009-03-27 | 2012-10-04 | 杏林製薬株式会社 | 塩基性添加剤を含有するマトリックス型徐放性製剤 |
| AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
| CN107115530A (zh) | 2009-11-27 | 2017-09-01 | 勃林格殷格翰国际有限公司 | 基因型糖尿病患者利用dpp‑iv抑制剂例如利拉利汀的治疗 |
| EP2547339A1 (de) | 2010-03-18 | 2013-01-23 | Boehringer Ingelheim International GmbH | Kombination eines gpr119-agonisten und des dpp-iv-hemmers linagliptin zur verwendung bei der behandlung von diabetes und zugehöriger erkrankungen |
| US20130023494A1 (en) | 2010-04-06 | 2013-01-24 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| AU2011249722B2 (en) | 2010-05-05 | 2015-09-17 | Boehringer Ingelheim International Gmbh | Combination therapy |
| KR20220025926A (ko) | 2010-06-24 | 2022-03-03 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
| JP2013216580A (ja) * | 2010-08-06 | 2013-10-24 | Kyorin Pharmaceutical Co Ltd | ビシクロ［２．２．２］オクチルアミン誘導体の製造方法 |
| BR112013008100A2 (pt) | 2010-09-22 | 2016-08-09 | Arena Pharm Inc | "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles." |
| WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US20140066369A1 (en) | 2011-04-19 | 2014-03-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| US20140038889A1 (en) | 2011-04-22 | 2014-02-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
| MX366820B (es) * | 2013-03-14 | 2019-07-25 | Bristol Myers Squibb Co | Moduladores de gpr120 del acido biciclo[2.2.2]. |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
| US20020006899A1 (en) | 1998-10-06 | 2002-01-17 | Pospisilik Andrew J. | Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals |
| DE19616486C5 (de) | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
| US5965764A (en) | 1997-08-06 | 1999-10-12 | Toray Industries, Inc. | Process for producing a nitrile |
| US20030176357A1 (en) | 1998-10-06 | 2003-09-18 | Pospisilik Andrew J. | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels |
| CO5150173A1 (es) * | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| AU3268500A (en) | 1999-03-19 | 2000-10-09 | Anormed Inc. | Pharmaceutical compositions comprising metal complexes |
| US20040152745A1 (en) | 1999-11-12 | 2004-08-05 | Guilford Pharmaceuticals, Inc. | Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors |
| WO2001034594A1 (en) | 1999-11-12 | 2001-05-17 | Guilford Pharmaceuticals, Inc. | Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors |
| US6380398B2 (en) * | 2000-01-04 | 2002-04-30 | Novo Nordisk A/S | Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
| EP1254113A1 (de) * | 2000-01-24 | 2002-11-06 | Novo Nordisk A/S | N-substituierte 2-cyanopyrrole und -pyrroline die inhibitoren des enzyms ddp-ivsind |
| US7064145B2 (en) * | 2000-02-25 | 2006-06-20 | Novo Nordisk A/S | Inhibition of beta cell degeneration |
| US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| TW583185B (en) | 2000-06-13 | 2004-04-11 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same |
| US6432969B1 (en) * | 2000-06-13 | 2002-08-13 | Novartis Ag | N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| TW540248B (en) | 2000-07-19 | 2003-07-01 | Koninkl Philips Electronics Nv | Method and device for generating a multiplexed MPEG signal |
| EP1950199B1 (de) * | 2000-08-10 | 2009-12-02 | Mitsubishi Tanabe Pharma Corporation | Prolinderivative und deren Verwendung als Medikamente |
| US20020037829A1 (en) | 2000-08-23 | 2002-03-28 | Aronson Peter S. | Use of DPPIV inhibitors as diuretic and anti-hypertensive agents |
| IL154893A0 (en) * | 2000-10-06 | 2003-10-31 | Tanabe Seiyaku Co | Aliphatic nitrogen-containing cyclic compounds, methods for the preparation thereof and pharmaceutical compositions containing the same |
| JP4329291B2 (ja) * | 2000-10-06 | 2009-09-09 | 田辺三菱製薬株式会社 | 含窒素五員環化合物 |
| JP4329290B2 (ja) | 2000-10-06 | 2009-09-09 | 田辺三菱製薬株式会社 | 脂肪族含窒素五員環化合物 |
| TWI243162B (en) * | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
| CZ20032321A3 (en) * | 2001-02-02 | 2004-03-17 | Takeda Chemical Industries, Ltd. | Fused heterocyclic compounds |
| WO2003000180A2 (en) * | 2001-06-20 | 2003-01-03 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| CN1990469A (zh) * | 2001-06-27 | 2007-07-04 | 史密丝克莱恩比彻姆公司 | 作为二肽酶抑制剂的氟代吡咯烷 |
| DE60223920T2 (de) * | 2001-06-27 | 2008-11-13 | Smithkline Beecham Corp. | Pyrrolidine als dipeptidyl-peptidase-inhibitoren |
| WO2003002553A2 (en) * | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| ATE388951T1 (de) | 2001-07-03 | 2008-03-15 | Novo Nordisk As | Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes |
| US6869947B2 (en) * | 2001-07-03 | 2005-03-22 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
| UA74912C2 (en) * | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
| AU2002360732A1 (en) | 2001-12-26 | 2003-07-24 | Guilford Pharmaceuticals | Change inhibitors of dipeptidyl peptidase iv |
| HUP0200849A2 (hu) | 2002-03-06 | 2004-08-30 | Sanofi-Synthelabo | N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra |
| DE60322857D1 (de) | 2002-03-25 | 2008-09-25 | Nippon Kayaku Kk | Neues alpha-amino-n-(diaminophosphinyl)lactamderivat |
| JP4329381B2 (ja) | 2002-04-04 | 2009-09-09 | 田辺三菱製薬株式会社 | 医薬組成物 |
| JP4329382B2 (ja) | 2002-04-04 | 2009-09-09 | 田辺三菱製薬株式会社 | 医薬組成物 |
| US20040106802A1 (en) * | 2002-04-08 | 2004-06-03 | Torrent Pharmaceuticals Ltd. | Novel compounds and therapeutic uses thereof |
| CN1633420A (zh) * | 2002-04-08 | 2005-06-29 | 托伦脱药品有限公司 | 噻唑烷－4－腈和类似物以及它们作为二肽基－肽酶抑制剂的用途 |
| JP2004026820A (ja) | 2002-05-09 | 2004-01-29 | Taisho Pharmaceut Co Ltd | ジペプチジルペプチダーゼｉｖ阻害剤 |
| AU2003235913A1 (en) | 2002-05-09 | 2003-11-11 | Taisho Pharmaceutical Co., Ltd. | Cyanopyrrolidine derivatives |
| HUP0202001A2 (hu) | 2002-06-14 | 2005-08-29 | Sanofi-Aventis | DDP-IV gátló hatású azabiciklooktán- és nonánszármazékok |
| GB0214344D0 (en) | 2002-06-21 | 2002-07-31 | Givaudan Sa | New odorant Compounds |
| AU2003248259A1 (en) | 2002-07-10 | 2004-02-02 | Yamanouchi Pharmaceutical Co., Ltd. | Novel azetidine derivative or salt thereof |
| TW200401635A (en) * | 2002-07-23 | 2004-02-01 | Yamanouchi Pharma Co Ltd | 2-Cyano-4-fluoropyrrolidine derivative or salt thereof |
| US20040121964A1 (en) | 2002-09-19 | 2004-06-24 | Madar David J. | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
| MXPA05003091A (es) | 2002-09-19 | 2005-05-27 | Abbott Lab | Composiciones farmaceuticas como inhibidores de peptidasa de dipeptidilo-iv de (dpp-iv). |
| AU2003902260A0 (en) | 2003-05-09 | 2003-05-29 | Fujisawa Pharmaceutical Co., Ltd. | Dpp-iv inhibitor |
| DK3366283T3 (da) | 2004-01-20 | 2021-11-22 | Novartis Ag | Direkte sammenpresningsformulering og fremgangsmåde |
| SI1712547T1 (sl) * | 2004-02-05 | 2012-04-30 | Kyorin Seiyaku Kk | Bicikloestrski derivat |
| CN1922139B (zh) * | 2004-02-18 | 2010-12-29 | 杏林制药株式会社 | 双环酰胺衍生物 |
| US7514571B2 (en) * | 2004-02-27 | 2009-04-07 | Kyorin Pharmaceutical Co., Ltd. | Bicyclo derivative |
| TWI415635B (zh) | 2004-05-28 | 2013-11-21 | 必治妥施貴寶公司 | 加衣錠片調製物及製備彼之方法 |
| PE20060652A1 (es) | 2004-08-27 | 2006-08-11 | Novartis Ag | Composiciones farmaceuticas de liberacion inmediata que comprenden granulos de fusion |
| NZ554515A (en) | 2004-10-12 | 2009-12-24 | Glenmark Pharmaceuticals Sa | Novel dipeptidyl peptidase IV inhibitors, pharmaceutical compositions containing them, and process for their preparation |
| JP2008019168A (ja) | 2004-10-22 | 2008-01-31 | Astellas Pharma Inc | ２−シアノ−４−フルオロピロリジン誘導体の製造法 |
| JP2006160733A (ja) | 2004-11-15 | 2006-06-22 | Taisho Pharmaceut Co Ltd | シアノフルオロピロリジン誘導体を有効成分として含有する医薬 |
| GT200600008A (es) | 2005-01-18 | 2006-08-09 | Formulacion de compresion directa y proceso | |
| MY152185A (en) | 2005-06-10 | 2014-08-29 | Novartis Ag | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
| CA2645154C (en) | 2006-03-08 | 2011-11-29 | Kyorin Pharmaceutical Co., Ltd. | Method for producing aminoacetylpyrrolidinecarbonitrile derivative and production intermediate thereof |
| JP2010120851A (ja) | 2007-02-09 | 2010-06-03 | Kyorin Pharmaceut Co Ltd | 二量化シクロ誘導体 |
| ATE550319T1 (de) | 2007-03-22 | 2012-04-15 | Kyorin Seiyaku Kk | Verfahren zur herstellung eines aminoacetylpyrrolidincarbonitrilderivats |
| JP2008239543A (ja) | 2007-03-27 | 2008-10-09 | Kyorin Pharmaceut Co Ltd | ビシクロアミノアセチルピロリジンカルボニトリル誘導体の製造方法およびその製造中間体 |
| JP2008290969A (ja) | 2007-05-24 | 2008-12-04 | Kyorin Pharmaceut Co Ltd | アミノアセチルピロリジン誘導体の製造方法 |
| JP2009114127A (ja) | 2007-11-07 | 2009-05-28 | Kyorin Pharmaceut Co Ltd | アミノアセチルピロリジンカルボニトリル誘導体の製造方法 |
-
2005
- 2005-02-01 SI SI200531480T patent/SI1712547T1/sl unknown
- 2005-02-01 PT PT05704327T patent/PT1712547E/pt unknown
- 2005-02-01 CN CN200910175524A patent/CN101684089A/zh active Pending
- 2005-02-01 EP EP05704327A patent/EP1712547B1/de active Active
- 2005-02-01 BR BRPI0506622-0A patent/BRPI0506622A/pt not_active IP Right Cessation
- 2005-02-01 RS RS20120076A patent/RS52163B/en unknown
- 2005-02-01 ES ES05704327T patent/ES2375625T3/es active Active
- 2005-02-01 AU AU2005210285A patent/AU2005210285B2/en not_active Ceased
- 2005-02-01 WO PCT/JP2005/001377 patent/WO2005075421A1/ja active Application Filing
- 2005-02-01 NZ NZ548440A patent/NZ548440A/xx not_active IP Right Cessation
- 2005-02-01 CA CA2554493A patent/CA2554493C/en not_active Expired - Fee Related
- 2005-02-01 JP JP2005517671A patent/JP3954626B2/ja not_active Expired - Fee Related
- 2005-02-01 AT AT05704327T patent/ATE537141T1/de active
- 2005-02-01 CN CN2005800041918A patent/CN1918119B/zh not_active Expired - Fee Related
- 2005-02-01 KR KR1020067015699A patent/KR101130433B1/ko not_active IP Right Cessation
- 2005-02-01 US US10/588,660 patent/US7754757B2/en not_active Expired - Fee Related
- 2005-02-01 PL PL05704327T patent/PL1712547T3/pl unknown
- 2005-02-01 DK DK05704327.5T patent/DK1712547T3/da active
-
2006
- 2006-07-27 ZA ZA200606237A patent/ZA200606237B/xx unknown
- 2006-07-31 NO NO20063486A patent/NO20063486L/no not_active Application Discontinuation
-
2007
- 2007-05-30 HK HK07105747.8A patent/HK1100511A1/xx not_active IP Right Cessation
-
2009
- 2009-12-08 US US12/654,018 patent/US8053465B2/en not_active Expired - Fee Related
-
2011
- 2011-12-21 CY CY20111101277T patent/CY1112550T1/el unknown
-
2012
- 2012-01-03 HR HR20120006T patent/HRP20120006T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1712547A1 (de) | 2006-10-18 |
| ZA200606237B (en) | 2007-12-27 |
| CY1112550T1 (el) | 2016-02-10 |
| EP1712547B1 (de) | 2011-12-14 |
| US8053465B2 (en) | 2011-11-08 |
| PL1712547T3 (pl) | 2012-04-30 |
| CA2554493C (en) | 2012-06-26 |
| KR101130433B1 (ko) | 2012-03-27 |
| NZ548440A (en) | 2009-07-31 |
| US7754757B2 (en) | 2010-07-13 |
| WO2005075421A1 (ja) | 2005-08-18 |
| US20100093825A1 (en) | 2010-04-15 |
| CN1918119A (zh) | 2007-02-21 |
| HK1100511A1 (en) | 2007-09-21 |
| JP3954626B2 (ja) | 2007-08-08 |
| RS52163B (en) | 2012-08-31 |
| SI1712547T1 (sl) | 2012-04-30 |
| KR20060130641A (ko) | 2006-12-19 |
| EP1712547A4 (de) | 2007-09-26 |
| DK1712547T3 (da) | 2012-03-19 |
| PT1712547E (pt) | 2012-03-06 |
| AU2005210285A1 (en) | 2005-08-18 |
| AU2005210285B2 (en) | 2008-01-24 |
| ES2375625T3 (es) | 2012-03-02 |
| BRPI0506622A (pt) | 2007-05-02 |
| HRP20120006T1 (hr) | 2012-01-31 |
| US20080146818A1 (en) | 2008-06-19 |
| NO20063486L (no) | 2006-08-29 |
| CA2554493A1 (en) | 2005-08-18 |
| CN1918119B (zh) | 2011-08-31 |
| JPWO2005075421A1 (ja) | 2007-10-11 |
| CN101684089A (zh) | 2010-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE537141T1 (de) | Bicycloesterderivat | |
| DE60210944D1 (de) | N-substituierte heterocyclische nichtaryl-nmda/nr2b-antagonisten | |
| BRPI0412851A (pt) | benzamidazóis de n-metila-substituìdos | |
| CY1109722T1 (el) | Ενδιαμεσες ενωσεις για την παρασκευη της trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,73oxepino[4,5-c]pyrrole | |
| BR0110998A (pt) | Derivados de fenilglicina | |
| BR0309669A (pt) | Compostos de anilina de pirrolo-triazina úteis como inibidores de cinase | |
| NO20020725L (no) | Celleadhesjonsinhibitorer | |
| WO2006100082A3 (de) | Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung | |
| DK1525177T3 (da) | Substituerede 1,3-diphenylprop-2-en-1-on-derivater, fremstilling og anvendelse deraf | |
| EA200801083A1 (ru) | Новые производные дигидропсевдоэритромицина | |
| NO20054787D0 (no) | Indenderivater som farmasotiske midler | |
| WO2008096841A1 (ja) | 二量化シクロ誘導体 | |
| DK1675591T3 (da) | Farmaceutisk sammensætning omfattende en monoamin-neurotransmitter-genoptagelseshæmmer og en acetylcholinesterase-hæmmer | |
| WO2007098030A8 (en) | Selective n-sulfonylation of 2-amino trifluoroalkyl substituted alcohols | |
| ATE322487T1 (de) | Hydroxamsäure-derivate | |
| DK1379508T3 (da) | N-(aryl)-2arylethensulfonamider og terapeutiske anvendelser deraf | |
| NO20055602L (no) | 4,4-difluor-1,2,3,4-tetrahydro-5H-1-benzazepin-derivat og salt derav | |
| BRPI0516057A (pt) | derivados de indol como inibidores da ciclase de adenilato solúvel | |
| DK1017681T3 (da) | Hydrazon-benzazulenderivater, farmaceutiske præparater og mellemprodukter | |
| ATE491709T1 (de) | Pyrrolidinohydrochinazoline | |
| UY27628A1 (es) | "2'-halo -3',5'-dialcoxi-fen-1'il-2-imidazolidinas y su uso como un fármaco" | |
| WO2004099129A3 (en) | Intermediates useful in the synthesis of hiv-protease inhibitors and methods for preparing the same | |
| ITVI20020238A1 (it) | Macchina spaccatrice perfezionata. |